- Home
- MYGN vs LXEO Comparison
MYGN vs LXEO Comparison
Compare MYGN & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MYGN | LXEO |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.2M | 387.1M |
| IPO Year | 1996 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MYGN | LXEO |
|---|---|---|
| Price | $5.45 | $4.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $7.64 | ★ $18.44 |
| AVG Volume (30 Days) | ★ 1.5M | 788.8K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $771,400,000.00 | $654,000.00 |
| Revenue This Year | $6.86 | N/A |
| Revenue Next Year | $5.45 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2.33 | N/A |
| 52 Week Low | $3.53 | $3.60 |
| 52 Week High | $8.59 | $10.99 |
Technical Indicators
Market Signals| Indicator | MYGN | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 70.39 | 48.58 |
| Support Level | $4.24 | $4.44 |
| Resistance Level | $5.52 | $6.26 |
| Average True Range (ATR) | 0.30 | 0.35 |
| MACD | 0.11 | 0.09 |
| Stochastic Oscillator | 95.44 | 61.83 |
Price Performance
Historical ComparisonAbout MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.